- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00153140
Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
February 6, 2013 updated by: Braintree Laboratories
The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.
Study Overview
Study Type
Interventional
Enrollment
239
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36693
-
-
Arizona
-
Glendale, Arizona, United States, 85306
-
-
California
-
Anaheim, California, United States, 92801
-
Sacramento, California, United States, 95825
-
San Diego, California, United States, 92103
-
-
Florida
-
Lake Worth, Florida, United States, 33461
-
Largo, Florida, United States, 33770
-
St. Petersburg, Florida, United States, 33707
-
-
Maryland
-
Laurel, Maryland, United States, 20707
-
-
Massachusetts
-
Brighton, Massachusetts, United States, 02135
-
-
Missouri
-
St. Louis, Missouri, United States, 63017
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
-
Raleigh, North Carolina, United States, 27612
-
Winston-Salem, North Carolina, United States, 27103
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
-
-
Texas
-
Austin, Texas, United States, 78705
-
Dallas, Texas, United States, 75234
-
Fort Worth, Texas, United States, 76135
-
San Angelo, Texas, United States, 76904
-
-
Utah
-
Salt Lake City, Utah, United States, 84121
-
-
Virginia
-
Newport News, Virginia, United States, 23606
-
Norfolk, Virginia, United States, 23502
-
Richmond, Virginia, United States, 23294
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female outpatients at least 18 years of age
- Constipated according to ROME I criteria
- If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, double- barrier method, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study
- Are otherwise in good health, as judged by a physical examination
- In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent
Exclusion Criteria:
- Patients with heme positive stool at screening that is not associated with hemorrhoids or anal fissures.
- Patients with hypo- or hyperthyroidism as determined by medical history.
- Patients with severe renal impairment.
- Patients with moderate or severe hepatic impairment.
- Patients with known or suspected perforation or obstruction.
- History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
- Patients with symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.
- Patients with a known history of organic cause for their constipation.
Patients currently taking, or planning to take any of the following medications that are known to effect bowel habits:
- Antidiarrheals
- Antacids containing magnesium or aluminum salts
- Anticholinergics
- Antispasmodic agents
- Erythromycin and other macrolides
- Octreotide
- Lotronex, Zofran, or other 5-HT3 antagonists
- Zelnorm, or other 5-HT4 agonists
- Opiods/narcotic analgesics
- Prokinetics
- Serotonin re-uptake inhibitors or tricyclic antidepressants
- Calcium antagonists
- Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
- Female patients of childbearing potential who refuse a pregnancy test.
- Patients with a known allergy to tegaserod (or any of its excipients) or polyethyleneglycol.
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Patients who, within the past 30 days have participated in an investigational clinical study.
- Patients that have undergone a colonoscopy within 30 days of screening
- Patients that are currently taking, or have previously been treated with polyethyleneglycol3350 or tegaserod.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria
|
Secondary Outcome Measures
Outcome Measure |
---|
Analysis of individual ROME I criteria
|
Safety (adverse event review)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jorge Herrera, MD, University of South Alabama
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Primary Completion (Actual)
October 1, 2004
Study Registration Dates
First Submitted
September 7, 2005
First Submitted That Met QC Criteria
September 7, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
February 7, 2013
Last Update Submitted That Met QC Criteria
February 6, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 851-ZCC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
-
University of AlexandriaRecruitingFunctional ConstipationEgypt
Clinical Trials on polyethyleneglycol3350
-
Braintree LaboratoriesCompletedConstipationUnited States
-
Braintree LaboratoriesCompleted
-
Braintree LaboratoriesCompletedConstipationUnited States
-
Braintree LaboratoriesCompleted